Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Analyst Optimism | Discover why analysts maintain bullish outlook on Eli Lilly, with price targets ranging from $970 to $1,250, reflecting strong growth prospects and market position |
Pipeline Potential | Delve into Eli Lilly's promising pipeline, including oral GLP-1 agonist orforglipron, poised to revolutionize diabetes and obesity treatment markets |
Financial Forecast | Explore Eli Lilly's robust 2025 guidance, projecting revenues between $58-61 billion, surpassing consensus estimates and reflecting confidence in growth trajectory |
GLP-1 Market Leade | Eli Lilly's dominance in diabetes and obesity treatments, driven by Mounjaro and Zepbound, propels impressive 32% revenue growth despite recent challenges |
Metrics to compare | LLY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLLYPeersSector | |
---|---|---|---|---|
P/E Ratio | 72.0x | 9.5x | −0.5x | |
PEG Ratio | 0.69 | 0.00 | 0.00 | |
Price / Book | 53.8x | 1.8x | 2.6x | |
Price / LTM Sales | 16.9x | 3.4x | 2.9x | |
Upside (Analyst Target) | 22.5% | 83.0% | 57.2% | |
Fair Value Upside | Unlock | 17.6% | 8.9% | Unlock |